SARS-CoV-2 vaccines and myocarditis.

Area of Science:

• Immunology
• Cardiology
• Public Health

Background:

• The COVID-19 pandemic spurred rapid vaccine development, with mRNA vaccines proving highly effective against SARS-CoV-2.
• Post-vaccination pharmacovigilance identified a rare but notable risk of cardiac inflammation (myocarditis/pericarditis).
• This adverse event is most frequently observed in younger males within one week of receiving the second mRNA vaccine dose.

Purpose of the Study:

• To review the current evidence regarding SARS-CoV-2 vaccine-related myocarditis and pericarditis.
• To summarize existing clinical guidelines for managing this specific adverse event.

Main Methods:

• Systematic review of published literature.
• Analysis of pharmacovigilance data.
• Synthesis of international clinical recommendations.

Main Results:

• mRNA COVID-19 vaccines are associated with a small incidence of myocarditis and pericarditis.
• The risk is highest in males under 40, particularly after the second vaccine dose.
• Most cases are mild and resolve with standard treatment.

Conclusions:

• While vaccine-related myocarditis is a concern, the benefits of COVID-19 vaccination outweigh the risks.
• Adherence to updated clinical guidelines is crucial for prompt diagnosis and management.
• Continued monitoring and research are necessary to fully understand and mitigate this rare side effect.